When a medical device’s risk profile requires clinical investigation, early decisions regarding clinical evidence requirements, study design, market prioritization and regulatory engagement can significantly influence development timelines, regulatory acceptance and overall US and EU market entry strategy. Clinical investigations can be complex, time-consuming, and expensive, so strategic planning early in design and development is essential.

In this webinar, hosted by Elsevier, Donawa Lifescience President, Maria E. Donawa, M.D., among other expert speakers, examined key strategic decisions involved in planning clinical evidence for US and EU medical device market entry. The webinar took place on Wednesday, June 3, 2026, 10:00 a.m. Eastern Time (US & Canada).

Over 300 attendees gained a practical framework for planning clinical evidence strategies that support effective and efficient US and EU medical device market entry.

Key takeaways:

• Key considerations for identifying US and EU clinical evidence requirements early in design and development
• Key considerations in determining which safety and performance requirements need clinical data
• When multi-stage clinical investigations may be needed (e.g., first-in-human, pilot, pivotal)
• When to prioritize US vs. EU market entry and how that decision impacts clinical evidence strategy
• How to address differing US and EU expectations for clinical evidence quality and acceptability
• When and how to engage FDA and EU Notified Bodies as part of clinical evidence strategy